Streetbeat News

HRMY

Harmony Biosciences Holdings, Inc.

https://www.harmonybiosciences.com

Industry

Biotechnology

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

Open

34.52

Mkt cap

2B

Volume

220K

High

35.37

P/E Ratio

16.50

52-wk high

41.61

Low

34.28

Div yield

N/A

52-wk low

22.89

Harmony Biosciences has reiterated its full-year 2024 net product revenue guidance, expecting revenue between $700 million and $720 million.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:33 am

Harmony Biosciences reported its Q3 2024 financial results, with adjusted EPS of $1.03 surpassing the estimated $0.67, and sales of $186.038 million exceeding the expected $184.056 million.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 11:31 am

Harmony Biosciences (NASDAQ:HRMY) is set to release its quarterly earnings report on October 29, 2024. Analysts expect an EPS of $0.66. Investors are keen on not just an earnings beat but also positive future guidance. The company's past performance shows a tendency for share price changes post-earnings announcements.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 7:01 pm

Raymond James analyst Danielle Brill has reinstated an Outperform rating on Harmony Biosciences (NASDAQ:HRMY) with a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:03 pm

Mizuho analyst Graig Suvannavejh maintains an Outperform rating on Harmony Biosciences and raises the price target from $42 to $52.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:37 pm

Harmony Biosciences (NASDAQ:HRMY) has been analyzed by 6 analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target is $52.67, with a high of $56.00 and a low of $52.00. The company has shown strong revenue growth and profitability, but its ROE is below industry benchmarks.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 1:01 pm

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $52.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 10:24 am

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $52.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 9:30 am

Needham analyst Ami Fadia has reiterated a Buy rating on Harmony Biosciences with a maintained price target of $52.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 10:37 am

Harmony Biosciences is seeing strong growth with its drug Wakix, which has increased sales and patient numbers. UBS has initiated coverage with a Buy rating and a $56 price target, citing potential growth in the narcolepsy market and recent strategic acquisitions.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 6:56 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.